Institutional members access full text with Ovid®

Share this article on:

New Drug for Sickle Cell Disease

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: November 2017 - Volume 117 - Issue 11 - p 20–21
doi: 10.1097/01.NAJ.0000526743.46055.ef
Drug Watch
  • Endari (L-glutamine oral powder), an amino acid, is the first new treatment for sickle cell disease approved in nearly 20 years. Approved for use in those ages five years and older, Endari reduces the severe complications of sickle cell disease.
  • The most common adverse effects of Endari include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain, and chest pain.

Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: daschenbrenner@ndm.edu.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.